Philosopher's stone

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
수요일, 1월 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
수요일, 1월 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes

Retrieved on: 
수요일, 11월 15, 2023
Diet, Physician, Liraglutide, Insulin, Exercise, Clinical trial, Overweight, T2D, CGM, DSM-IV codes, Week, Type 2 diabetes, Obesity, Therapy, MD, Doctor of Philosophy, Diabetes, Medical imaging, Medical device, T1D, Philosopher's stone

BERKELEY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, today announced that it has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult participants with overweight or obesity with T1D.

Key Points: 
  • In addition to the Phase 2 clinical trial announced today, Carmot has an ongoing Phase 1b active comparator crossover clinical trial to assess the effects of CT-868 treatment on glucose homeostasis compared to liraglutide in participants with T1D.
  • CT-868 is one of three clinical-stage product candidates in Carmot’s pipeline of therapeutics for the potential treatment of obesity and diabetes.
  • Carmot anticipates enrolling approximately 95 participants at clinical trial centers across the United States.
  • Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels, diet and exercise recommendations.

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek®

Retrieved on: 
일요일, 10월 15, 2023
Type 2 diabetes, RA, Insulin, Pharmacokinetics, Doctor of Philosophy, Obesity, Insulin resistance, T2D, Weight loss, Central nervous system, MD, Physician, Risk, Therapy, OGTT, Diabetes, GIP, Safety, MOA, Overweight, Glucose, DSM-IV codes, Patient, Poster, Pharmaceutical industry, Medical device, Medical imaging, Philosopher's stone

DALLAS, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people with metabolic diseases, today announced positive results from the following studies: a study of CT-388 to evaluate the safety/tolerability, efficacy, and pharmacokinetics of CT-388 in people with overweight/obesity without type 2 diabetes (T2D), a study of CT-868 assessing the efficacy and safety of CT-868 in overweight/obese patients with T2D, and a preclinical mechanism of action (MOA) study to investigate the impact of a unimolecular dual biased GLP-1/GIP receptor agonist (RA) in regulating weight loss and food intake. The results are summarized in three poster presentations taking place at ObesityWeek® October 14-17, 2023.

Key Points: 
  • An oral glucose tolerance test was performed on Day -1 (baseline) and Day 23 (post the 4th dose).
  • CT-388 dosed at 5/8/12/12 mg produced 8.4% weight loss (~17 lbs) accompanied by a decrease in waist and hip circumference.
  • Overall, these data support further clinical evaluation of CT-388, with higher doses while maintaining and exploring simpler titration schemes, for the treatment of obesity, T2D and other weight-related comorbidities.
  • Carmot has designed the ongoing Phase 1/2 CT-388 clinical trial to evaluate a higher starting dose, a higher maximum dose and simpler titration schemes.

Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996

Retrieved on: 
화요일, 10월 10, 2023
Type 2 diabetes, RA, Doctor of Philosophy, Obesity, T2D, Weight loss, MD, Physician, Therapy, Diabetes, Overweight, SAD, Clinical trial, DSM-IV codes, Pharmaceutical industry, Vaccine, Philosopher's stone

Preliminary Phase 1 pharmacokinetic (PK) results support once-daily (QD) oral dosing of CT-996.

Key Points: 
  • Preliminary Phase 1 pharmacokinetic (PK) results support once-daily (QD) oral dosing of CT-996.
  • Tolerability results have been consistent with the GLP-1 RA class with the majority of the adverse events being gastrointestinal-related and mostly mild in severity.
  • “We are very pleased to see these preliminary results following single dose administration of CT-996,” said Manu Chakravarthy, MD, PhD, Carmot’s Chief Scientific & Medical Officer.
  • “We believe that the potential to offer a convenient, once-daily oral GLP-1 RA intervention as an alternative to an injection to treat obesity and its comorbidities, such as type 2 diabetes, could be transformative.

Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting

Retrieved on: 
화요일, 9월 26, 2023
Volunteering, Obesity, Human body weight, MOA, Therapy, T1D, Weight loss, Clinical trial, Type 2 diabetes, Pharmacokinetics, PYY, DSM-IV codes, Patient, CEST, Overweight, GIP, European Association for the Study of Diabetes, T2D, Diabetes, Medical imaging, Birth control, Communications satellite, Vaccine, Philosopher's stone

BERKELEY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to delivering life-changing therapeutics for people with metabolic diseases, today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany. Details regarding the clinical data presentations are as follows:

Key Points: 
  • Carmot expects to initiate additional Phase 2 trials for obesity and T2D.
  • Carmot has recently initiated an additional Phase 1 MOA study in adults with overweight/obesity with type 1 diabetes (T1D) and expects to initiate a Phase 2 proof-of-concept clinical trial in participants with overweight/obesity with T1D.
  • CT-996 (once-daily oral, small molecule GLP-1 receptor agonist) is currently in a multi-arm, multi-cohort Phase 1 clinical trial in adults with overweight/obesity as well as in patients with T2D.
  • A long-acting peptide tyrosine-tyrosine (PYY) analogue, which is in preclinical development.

Carmot Therapeutics Appoints Charles W. Newton to Board of Directors

Retrieved on: 
수요일, 7월 19, 2023
Newton, Morgan Stanley, Tuck School of Business, BS, Obesity, Diabetes, Lehman Brothers, BofA Securities, MBA, Dartmouth College, Credit Suisse, Miami University, DSM-IV codes, Patient, Growth, Bank, Therapy, Pharmaceutical industry, Philosopher's stone, Finance, Lyell

BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.

Key Points: 
  • BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.
  • “It’s with great pleasure that we welcome Charlie to the Carmot Board of Directors—we look forward to his guidance as we navigate the exciting opportunities that lie ahead,” said Heather Turner, CEO of Carmot Therapeutics.
  • Mr. Newton commented, "This is an exciting time for Carmot as they advance multiple programs with the goal of treating obesity and diabetes with novel incretin modulators.
  • Mr. Newton earned his MBA from the Tuck School at Dartmouth College as well as a BS in Finance from Miami University.

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions

Retrieved on: 
토요일, 6월 24, 2023
Hyperinsulinemia, Insulin, Obesity, American Diabetes Association, MOA, Diabetes, Type 2 diabetes, Glucose, Aes, Weight loss, Clinical trial, Pharmacokinetics, SAD, Liraglutide, MSCS, Appetite, Doctor of Philosophy, Trial of the century, Blood, GPCR, University of Texas Southwestern Medical Center, DSM-IV codes, Patient, SAN, Internal medicine, Annual general meeting, Overweight, GIP, MAD, Poster, MPH, Therapy, ADA, T2D, Physician, Pharmacology, Safety, Human, Pharmaceutical industry, Medical imaging, Dietary supplement, Medical device, Philosopher's stone, T1D, MD

SAN DIEGO, June 23, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced positive results from the following studies: a Phase 1 clinical trial of CT-388 assessing safety, tolerability, pharmacokinetics and pharmacodynamic activity in overweight and obese otherwise healthy participants, a mechanism of action (MOA) clinical study of CT-868 in overweight and obese adults with type 2 diabetes (T2D) to assess weight independent effects on glucose homeostasis, and a preclinical study in rodent models of type 1 diabetes (T1D) to support the effects of CT-868 as an adjunct to insulin treatment. The results are summarized in three poster presentations taking place at the American Diabetes Association (ADA) Annual Meeting (June 23-26, 2023).

Key Points: 
  • The results are summarized in three poster presentations taking place at the American Diabetes Association (ADA) Annual Meeting (June 23-26, 2023).
  • “We are extremely excited about the results from our CT-388 and CT-868 dual GLP-1/GIP receptor modulator programs to date.
  • These data warrant further clinical evaluation of CT-388, possibly with minimal to no titration, for the treatment of obesity, type 2 diabetes and other weight-related comorbidities.
  • Carmot has designed the Phase 1/2 CT-388 clinical trial to evaluate not only higher doses across longer treatment durations (e.g.

Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer

Retrieved on: 
화요일, 6월 6, 2023
Volunteering, Human resources, Business development, IPO, Obesity, MOA, Benjamin Arsanis, Bryant University, Diabetes, T1D, Facility, Clinical trial, Business, Babson College, PYY, Grey, Sale, Acquisition, DSM-IV codes, Patient, CBO, Overweight, CFO, Therapy, T2D, Pharmaceutical industry, Management, Vaccine, Philosopher's stone

BERKELEY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).

Key Points: 
  • BERKELEY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).
  • In addition, Gray will lead cross-functional teams that include Business Development, Human Resources, IT and Facilities.
  • Gray joins Carmot with nearly 20 years of public-private leadership experience including broad strategic, financial and operating experience in global companies.
  • I am honored to be joining Carmot, a company that is committed to transforming patients' lives through potentially differentiated therapies for metabolic diseases," stated Gray.

Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes

Retrieved on: 
목요일, 5월 25, 2023
Janus, Volunteering, Obesity, RA, MOA, Diabetes, T1D, Clinical trial, Millennium Management, LLC, PYY, Doctor of Philosophy, Patient, DSM-IV codes, Overweight, Column, Therapy, T2D, Disease, Vaccine, Medical imaging, Pharmaceutical industry, Philosopher's stone

BERKELEY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced a $150 million oversubscribed and up-sized Series E financing. The financing was led by Deep Track Capital. The syndicate also included new investors 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millennium Management, TCGX, Venrock Healthcare Capital Partners and existing investors RA Capital Management, The Column Group and Willett Advisors. The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.

Key Points: 
  • The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.
  • “With three clinical-stage candidates currently in development, this financing enables us to continue to advance clinical trials that will yield key data readouts this year and through 2024."
  • Results from the multiple ascending dose cohorts will be presented at the 83rd American Diabetes Association Scientific Sessions.
  • By making subtle improvements in molecular design, Carmot may be able to achieve clinically relevant tolerability and efficacy benefits.